Search results
TIME100 Health: Katalin Kariko and Drew Weissman
Time via Yahoo News· 6 hours agoIn under a year, both Pfizer-BioNTech and Moderna developed mRNA-based COVID-19 vaccines based on Kariko and Weissman’s method. The shots helped to slow...
Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025...
Benzinga· 1 hour agoThursday, Moderna Inc MRNA reported a first-quarter EPS loss of $(3.07), down from an income of...
The true tragedy of the Covid-19 vaccines
The Telegraph via Yahoo News· 1 day agoVaccination is one of mankind’s most miraculous innovations. The eradication of smallpox, and the retreat of measles and other cruel afflictions, mean...
Analysis | Whatever happened to Biden’s public option?
Washington Post· 6 days agoAs we ramp up for the 2024 election, I’ve wondered why talk of the public option has disappeared....
Arbutus Biopharma Corp Reports Q1 2024 Earnings: A Detailed Financial Review
GuruFocus.com via Yahoo Finance· 5 hours agoLitigation and Intellectual Property Updates Arbutus continues to defend its intellectual property vigorously, particularly in ongoing litigation with Moderna and Pfizer/& ...
TIME100 Health: Katalin Kariko and Drew Weissman
Time Magazine· 6 hours agoDr. Drew Weissman was working on developing an HIV vaccine, and Katalin Kariko was struggling to keep her lab open and convince her superiors that her...
Arbutus Biopharma Corp Reports Q1 2024 Earnings: A Detailed Fina
Guru Focus· 6 hours agoRevenue: Reported at $1.5 million for Q1 2024, a significant decrease from $6.7 million in Q1 2023, falling short of the estimated $2.15 million.Net Loss: Reco
Study confirms effectiveness of bivalent COVID-19 vaccine
Medical Xpress· 7 days agoThis was the first research project conducted to evaluate the immunity induced by the Pfizer-...
COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle -...
Benzinga· 6 days agoCanadian Biotech company Acuitas Therapeutics and Germany-based CureVac NV CVAC have settled...
Acuitas, CureVac settle lawsuit over COVID-19 vaccine patent rights
Reuters· 7 days agoBiotech company Acuitas Therapeutics and Germany-based CureVac have settled Acuitas' lawsuit...